Symptomatic treatment of benign prostatic obstruction with Nicergoline: A placebo controlled clinical study and urodynamic evaluation
Authors:
- 1 August 1982
- journal article
- Published by Springer Nature in Urological Research
- Vol. 10 (3) , 131-134
Abstract
A double-blind crossover study of the alphablocker Nicergoline was carried out in sixteen patients affected by benign prostatic bladder outflow obstruction. The “irritative” symptoms of prostatic hypertrophy, including nocturnal frequency and dysuria, were improved after Nicergoline significantly more than after placebo. In 10 further patients with prostatic hypertrophy, peak and mean flow rates increased by 50% and 77% respectively after the acute administration of Nicergoline. No side effects were detected. In conclusion Nicergoline seems to be active and well tolerated in the treatment of benign prostatic obstruction.Keywords
This publication has 11 references indexed in Scilit:
- Effect of megestrol acetate on uroflow rates in patients with benign prostatic hypertrophyUrology, 1979
- Alpha-adrenergic blockers in prostatismBritish Journal of Surgery, 1977
- The Analysis of the Two-Period Repeated Measurements Crossover Design with Application to Clinical Trials1977
- The Use of Alpha-adrenergic Blockers in Benign Prostatic ObstrucionBritish Journal of Urology, 1976
- The Effect of Bromocriptine in Patients with Benign Prostatic HypertrophyBritish Journal of Urology, 1976
- Study of the protection on afforded by nicergoline against the effects of cerebral ischemia in the cat.1975
- 328. Note: The Use of None-Parametric Methods in the Statistical Analysis of the Two-Period Change-Over Design1972
- A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophyBritish Journal of Surgery, 1971
- Vasodilating and alpha-receptor blocking activity of a new ergoline derivative.1968
- Hormonal Management of the Benign Obstructing Prostate: Use of Combined Androgen-Estrogen TherapyJournal of Urology, 1959